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Neuronal differentiation of induced pluripotent stem cells and direct reprogramming represent powerful methods for modeling
the development of neurons in vitro. Moreover, this approach is also a means for comparing various cellular phenotypes between
cell lines originating from healthy and diseased individuals or isogenic cell lines engineered to differ at only one or a few
genomic loci. Despite methodological constraints and initial skepticism regarding this approach, the field is expanding at a fast
pace. The improvements include the development of new differentiation protocols resulting in selected neuronal populations
(e.g., dopaminergic, GABAergic, hippocampal, and cortical), the widespread use of genome editing methods, and single-cell
techniques. A major challenge awaiting in vitro disease modeling is the integration of clinical data in the models, by selection
of well characterized clinical populations. Ideally, these models will also demonstrate how different diagnostic categories share
overlapping molecular disease mechanisms, but also have unique characteristics. In this review we evaluate studies with regard to
the described developments, to demonstrate how differentiation of induced pluripotent stem cells and direct reprogramming can
contribute to psychiatry.
1. Challenges in Psychiatric Research
Schizophrenia (SCZ) and bipolar disorder (BPD) present
with overlapping clinical symptomatology and share many
environmental and genetic risk factors (for a review see
[1]). Additionally, extended literature argues on the neu-
rodevelopmental origin and neuroprogressive course of both
syndromes. Although psychotic disorders and BPD are not
the most frequent psychiatric conditions, they affected 8
million people in Europe and costed C125 billion for the
society in 2010 according to the report of the European Brain
Council [2].
As mental disorders are exclusively human conditions,
investigating and modeling these conditions raise several
problems and necessitate compromises. Animal models,
based on rare mutations of large effects, provide valuable
information on the cellular biology and behavioral endophe-
notypes of psychiatric disorders but obviously have their
limitations and validation difficulties. Indeed, 92% of drugs
that passed preclinical studies fail in the clinical phase due to
lack of efficacy or safety reasons [3].
In vivo brain sampling in psychiatric patients or control,
healthy subjects is ethically and technically problematic.
Postmortem tissue samples are widely used for assessment
of architectural and molecular alterations in brain disorders,
but the results must be evaluated circumspectly regarding
the variability in the sampled brain area, the pre- and
postmortem circumstances and the consequent degradation
of RNAs and proteins. In order to countervail these technical
issues, brain banks provide great sample sizes, standardized
methodology, and detailed clinical information; however,
these samples are not appropriate for functional assays or
diagnostic purposes and the observed changes might be
evoked by comorbidities or environmental factors over the
course of the disease.
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The heritability of SCZ, BPD, and autism spectrum
disorders (ASD) is above 80% [4–6], but neither candidate
gene nor genome-wide association (GWA) studies can fully
explain this magnitude. These hidden genetics substantiated
the theory of raremutationswith large effects versus common
alleles with low penetrance [7]. Accordingly, in most of the
cases psychiatric diseases are multifactorial and thus derive
from the constellation of (otherwise harmless) common
susceptibility alleles and environmental factors. Cases caused
by single mutations occur very rarely and remain undetected
in large-scale studies. Additionally, recent studies suggested
that de novo mutations may have a great impact on the
individual susceptibility [8, 9]. In vitro cell culture models
represent a system-oriented view, in which mental disorders
are the manifestations of the donor’s individual genetics, and
along this line they enable performing functional assays to
map gene × environment (G × E) and gene × gene (G × G)
interactions.
2. Manufacturing Neurons: Made in Dish
Since detailed description of the iPSC/iNC induction and
differentiation would extend the limitations of this paper and
several publications have been already written on this rapidly
developing field, here we will only briefly summarize the
main technical issues (Figure 1). For further information and
comparison of different protocols see [92–94].
Currently, there are three methods to generate human
neural cells in vitro: iPSCs can be differentiated into neuronal
progenitor cells (NPCs) and somatic cells can be transdif-
ferentiated into neural stem cells or directly into neurons.
Interestingly, transdifferentiation experiments have not yet
been performed in the context of psychiatric disorders, even
though four transcription factors or two microRNAs are
enough to convert human fibroblasts into functional neurons
within three weeks [95, 96]. Direct conversion has the advan-
tage of bypassing the prolonged, potentiallymutagenic phases
of reprogramming and intensive progenitor proliferation
[97]. On the other hand, the amount of experimentalmaterial
is limited by the number of somatic cells and the efficacy of
the transdifferentiation.
Somatic cells can be reprogrammed into pluripotent stage
with a set of transcriptional factors, namely, OCT4, SOX2,
KLF4, and c-MYC or OCT4, SOX2, NANOG, and LIN28
[98, 99]. These can be entered into the cells via integrating
(lenti- and retroviral) or non-integrative (adenovirus, Sendai
virus, episomal vector, and synthetic mRNA) vectors or
direct protein delivering tools [100]. After initial induction,
endogenousNANOG, SOX2, andOCT3/4 expression indicate
pluripotency which can be maintained via basic fibrob-
last growth factor (bFGF) supplementation for theoretically
unlimited time.
The differentiation of iPSCs is thought to follow in vivo
developmental pathways and require environmental cues.
During the past eight years several protocols have been
developed based on monolayer dual SMAD inhibition [101]
or embryoid aggregates [102] with an efficacy of 80% or
more than 85%, respectively. (For a comparative review see
[103].) Successfully differentiated or transformed cells can
be easily recognized by the detection of PAX6, an early
forebrain neuronal marker. Since embryonic aggregate-based
techniques reduce the variability of differentiation potential
among pluripotent cells, it results in a more homogenous
cell population. However, the culture always contains pro-
genitors, glial cells, and mature or immature neurons with
different neurotransmitter and receptor profiles and varying
electrophysiological properties [13].
During manufacturing specific neurons, two major
approaches are available. (1) High neurotransmitter speci-
ficity can be evoked by viral vectors or the combina-
tion of growth factors/small molecules. GABAergic cortical
interneurons [104, 105], dopaminergic midbrain neurons
[106, 107], dentate gyrus granule cells, and glutamatergic
pyramidal neurons were successfully generated according to
these protocols with an efficacy above 90%. (2) On the other
hand, one can address the investigation of region and layer-
specific neurons. Remarkably, NPCs emerging from neural
rosettes show self-organized spatiotemporal differentiation
pattern and model the six-layered cortical structure. Bene-
fitting from this, researchers are able to cultivate and isolate
early and late cortical progenitors, preplate neurons, deep (V-
VI) and superficial (II–IV) layer neurons in a definite tem-
poral manner [108]. Furthermore, advents of biotechnologies
already allow us to grow neural and glial cells in 3D cul-
tures, forming functional organoids which resemble certain
brain regions on the cellular and tissue level [109]. These
microphysiological systems could be especially valuable
tools for modeling neurodevelopmental or neuroprogressive
diseases.
The basic requirements against differentiation are as
follows: quick and efficient generation of homogenous cell
populations with physiological (or diseased) characteristics.
The main concern about currently existing protocols is that
they frequently result in heterogeneous, asynchronic cell pop-
ulations with varying phenotypes and maturation states [13].
Remarkable efforts are made to develop cost-effective, large-
scale generation of NPCs and matured, synchronized neu-
rons for high-throughput assays [14, 110].
3. Closer to Perfection or Just Misperception?
iPSC/iNC cultures as model systems have advantages and
disadvantages: (1) the cell lines can be initiated from easily
obtainable biospecimens, for example, blood sample, skin
biopsy, hair follicle, or urine, (2) but the reprogramming,
culturing, and differentiation are labor intensive and require
notable expertise [111]. (3) iPSCs and iNPCs have self-
sustaining capacity, (4) while differentiated neurons are in
postmitotic state; hence they provide restricted experimental
material. (5) During reprogramming and differentiation the
cells undergo epigenetic rearrangement, (6) and proliferating
iPSCs exhibit genetic instability which may result in popu-
lation diversity and biases in genetic assays [112]. (7) Neuro-
transmitter and brain region specific neurons provide unique
opportunity to study the pathophysiology and genetics of
neuropsychiatric disorders, (8) but every new protocol has to
be carefully validated regarding the cell type-specific markers
and the analogies and discrepancies compared to in vivo and
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Figure 1: Schematic illustration of induced pluripotent stem cell and neural cell line generation and further clinical and research applications.
(iPSC: induced pluripotent stem cell; iNPC: induced neural progenitor cell; iN: induced neuron).
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Figure 2: (a), (b), and (c) Characteristics of current literature dealing with induced pluripotent/neural cell lines in psychiatric research. (c)
Represents the research articles only. Publications were reviewed until June, 2015.
animalmodel findings. (9) Finally, iPSC/iNC experiments are
time and money consuming.
4. Three Years’ Balance: Debits and Credits
In 2012, the National Institute of Mental Health (NIMH)
and the Foundation for the NIH organized a workshop on
the technological advances and challenges of patient-derived
iPSCs/iNCs research in psychiatry. Scientists and delegates
of industry and government and funding organizations
conceived recommendations and directions for the future
focusing on basic research, new target identification, and
drug development (for the meeting report see [10]). Since
stem cell biology and brain research are two of themost active
fields of life sciences, we decided to review systematically the
literature on iPSC/iNC in the context of psychiatric diseases
and strike a balance: Did we take our own advice? How far
have we got? What challenges do we face? (Table 1).
To give exact answers, we performed, first in the lit-
erature, a systematic review on iPSC/iNC based researches
in psychiatry. We searched PubMed with the following
keywords: “induced pluripotent OR reprogramming OR
transdifferentiation AND psychiatry OR schizophrenia OR
bipolar OR major depression OR autism” until 20 June, 2015.
First, we catalogued research papers, if (at least part of) the
experiment was conducted on human induced pluripotent
derived or transdifferentiated neural cell cultures and English
text was available. We excluded papers on neurodegenerative
disorders, dementias, and epilepsies (Table 2(a)). During the
survey, we noticed that review publications display outstand-
ing proportion of the literature (41%); thus we decided to list
the relevant reviews using the same criteria (Table 2(b)).
5. What Can (Should) Be Reviewed?
After categorizing the items, we found 80 relevant publi-
cations: 48 research articles and 33 reviews (Figures 2(a),
2(b), and 2(c)). Intriguingly, we did not find any papers with
iPSCs/iNCs targeting major depression. This is surprising,
since unipolar depression is the leading chronic disorder
in the WHO European Region, and the third cause of
disability-adjusted life-years (DALY) [113], while only half
of the patients receive adequate therapy with 70% long-
term efficacy [114]. Considering that major depression is
a multifactorial, neurobiological disorder with heritability
estimates between 40 and 60% [115] and peripheral cells
were traditionally used to model and study the diseased
endophenotypes [116–118], we can envisage that iPSCs/iNCs
hold great promise in this field.
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Table 1: Advancements and further challenges of the utility of induced pluripotent/neural cells in psychiatric research.The recommendations
were conceived on a meeting of the National Institute of Mental Health and the Foundation for NIH in 2012 [10].
Recommendations in 2012 Advancements in the past 3 years Challenges remain
Standardization of protocols
(i) Optimizing reprogramming and
differentiating methods
(ii) Efficient generation and validation of
specific neural cell types
(iii) The importance of region and
maturation state specific differentiation
(iv) Poorly defined regional identity
(i) Safe, integration-free, nonviral induction
(ii) Neurotransmitter and region specific
protocols with efficacy >80%
(iii) Multiple model based studies
(iv) Combination of GWAS databases with
iPSC/iNC observations
(i) Comparison of cells induced from
different peripheral tissues
(ii) Utility of induced glial cells in
psychiatric research
Improving homogeneity
(i) Detailed comparison of induced and
source cells to reveal de novo genetic
mutations
(ii) Multiple parallel cell lines from one
donor
(iii) Epigenetic mapping during
reprogramming and differentiation
(i) Vector integration-free, “safe” reprogramming
methods
(ii) Reassuring results on chromosomal mutations
(iii) Average 3 cell lines/donor
(iv) Experiments and reviews comparing the
available protocols
(i) Concerns on de novo CNVmutations
and the neuronal genome
(ii) Contradictions regarding epigenetics
(iii) Little is that known about
endogenous production of astrocytes
Increasing statistical power
(i) Increasing sample sizes
(ii) Careful selection and grouping of
subjects
(iii) Detailed clinical and genetic
characterization of subjects
(iv) Overthought diseased-control pairing
(i) Studies with whole genome sequencing and
whole transcriptome profiling
(ii) Isogenic case-control comparison (new DNA
editing techniques, twin studies)
(i) Increasing sample sizes
(ii) Reconsideration of patient grouping
(iii) Transparent, published case-control
matching
Improve reproducibility, resource sharing, and collaboration
(i) Establishing rigorous, transparent, and
reproducible methods
(ii) Detailed publication of protocols
(iii) Rapid sharing of cell lines, technologies,
and best practices
(iv) Improving public-private partnership
(i) iPSC banks combined with gene banks
(ii) Commercially available iPSCs, iCell neurons,
and knock-out cell lines with isogenic controls
(iii) Open access movements
(iv) Results usually correlated with postmortem
and animal model findings
(i) Guidelines for validation
(ii) Criteria for cell characterization
(markers, electrophysiological properties)
(iii) Poor publication of donor’s genotype,
clinical features
Towards large-scale studies
(i) Decreasing protocol diversity
(ii) Validation assays for phenotypic
comparison of derived cell lines
(i) Protocol diversity remains, but major steps
towards large-scale production
(ii) Commercially available cells provide enough
experimental material for high throughput assays
Personalized medicine requires
reprogramming and differentiation by
every single patient, which is still
remarkably time-consuming and money
consuming
Careful patient selection, case-control matching
(i) Subgrouping on the base of
comprehensive genetic and clinical
characterization
(ii) Linking genotype with molecular and
cellular pathophysiology
(i) Isogenic case-control pairs provided by DNA
editing techniques, twin studies
(ii) Pedigree-studies
(iii) DSM-5 reconsidered subcategories
Endophenotype-based subgrouping?
6. Evidence-Based Questions
iPSC/iNC studies are interpretable only in a multiscale
diseasemodeling paradigm; thus results fromawell-designed
experiment should raise more questions than those they
answer per se. Therefore, we examine the main issues
addressed at the 2012 NIMH workshop [10] and those which
emerged since via introducing some of the published studies
and focusing on answered and emerged future challenges.
6.1. Time Is Not Everything, but Timing! The 2012 work-
shop highly emphasized the need for effective, standardized
derivation and validation protocols for high-scale studies
and future clinical application of iPSC/iNC technologies [10].
The participants cautioned against proliferation of poorly
designed studies and recommended the establishment of
rigorous, transparent, and reproducible methodology.
Reviewing the literature, we can conclude that significant
progression was made in neural differentiation methods
during the past three years. Today, researchers are able to
generate neurons of regional and temporal identity, as well
as 3D organoids; however, the methods are still under intense
development formore efficient, time-sparing protocols. Since
we have to allow room for these innovations, validation
practices call for standardization.
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Table 2: (a) Research articles using induced pluripotent stem cells and/or induced neural cells in studying psychiatric disorders. (b) Review
articles on induced pluripotent stem cells and/or induced neural cells in modeling psychiatric disorders.
(a)
Author, publication
date Modeled disease(s) Main findings
Cell line,
differentiation protocol
Patient
derived
cell lines
Free
full text
Ananiev et al., 2011 [11] Rett syndrome Neurons exhibit smaller nuclear size Differentiatedglutamatergic neurons Y (3) Y
Bavamian et al., 2015
[12] BPD
miR-34a is associated with BPD and
neurodevelopment NPCs Y (1) N
Belinsky et al., 2014 [13] Neurodevelopment Electrophysiology and gene expressionduring neural maturation
Differentiated
glutamatergic neurons Y (1) Y
Boissart et al., 2013 [14] Psychopharmacology,ASD
Synchronous production of cortical
neurons for high-throughput assays
Glutamatergic cortical
neurons Y (2) Y
Brennand et al., 2011
[15] SCZ
Diminished connectivity, cAMP and
WNT signaling rescued by
antipsychotic treatment
Panneuronal
differentiation
protocol, glutamatergic
neurons
Y (4) Y
Brennand et al., 2015
[16] SCZ
Altered migration, mitochondrial
damage, and increased oxidative stress
NPCs, panneuronal
differentiation Y (4) Y
Brick et al., 2014 [17] ASD iPSC bank from ASD patients andcontrols
Differentiated
glutamatergic neurons
Y
(cell bank) Y
Bundo et al., 2014 [18] SCZ LINE retroelements show moreactivity in SCZ derived cells
Differentiated
glutamatergic neurons Y (3) Y
Chen et al., 2014 [19] BPD
BPD iNCs exhibit Ca-signaling and
neurodevelopment associated
transcription alterations
Differentiated neurons
(mixed glutamatergic-
GABAergic
populations)
Y (3) Y
Chen et al., 2013 [20] SCZ, BPD Transcriptional effects of zinc fingerprotein 804A silencing
Differentiated
glutamatergic neurons N Y
Cheung et al., 2011 [21] Rett syndrome Generation of MECP2 mutantiPSC/iNC lines and their isogenic pairs
Differentiated
glutamatergic neurons Y (1) Y
Chiang et al., 2011 [22] SCZ Introduction of an integration-freemethod for reprogramming iPSCs Y (2) Y
Corrales et al., 2012
[23] SCZ
Copy number variations in iPSCs,
iNCs NPCs Y
∗ N
Dage et al., 2014 [24] Psychopharmacology,ASD
Pharmacological and transcriptome
characterization of iNCs Forebrain neurons N N
DeRosa et al., 2012 [25] ASD iPSC and GABA neuron derivationfrom whole blood GABAergic neurons Y
∗ Y
Doers et al., 2014 [26] Fragile X syndrome iNCs show neurite outgrowth deficit Forebrain neurons Y (3) N
Germain et al., 2014
[27]
Neurodevelopmental
disorders
Gene expression analysis of iPSCs
from 15q11 variants
Differentiated
glutamatergic neurons Y (3) Y
Griesi-Oliveira et al.,
2014 [28] ASD TRPC6 gene is associated with ASD
Differentiated
glutamatergic neurons Y (1) N
Hashimoto-Torii et al.,
2014 [29] SCZ
Heat shock transcription factor 1
mediated stress response abnormalities
in a subpopulation of iNPCs
NPCs Y (4) Y
Hook et al., 2014 [30] SCZ Increased catecholaminerg neuralactivity in SCZ cell cultures
Panneuronal
differentiation protocol Y (4) Y
Chung et al., 2014 [31] Fragile X syndrome Development of a high-contentscreening assay NPCs Y
∗ N
Krey et al., 2013 [32] Timothy syndrome iNCs exhibit dendritic retractiondeficit
Differentiated
glutamatergic neurons Y (2) Y
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(a) Continued.
Author, publication
date Modeled disease(s) Main findings
Cell line,
differentiation protocol
Patient
derived
cell lines
Free
full text
Kumari et al., 2015 [33] Fragile X syndrome Development of a high-throughputscreening assay NPCs Y (3) N
Larimore et al., 2013
[34] Rett syndrome
MECP2 regulates synaptic expression
of dysbindin-BLOC1 pathway
Differentiated
glutamatergic neurons Y (2) Y
Lin et al., 2012 [35] SCZ Allele specific expression profile Differentiatedglutamatergic neurons Y (3) Y
Lin et al., 2014 [36] SCZ, ASD Heat shock alters SCZ, ASD-relatedgenes
3-dimensional
neuronal aggregates Y Y
Liu et al., 2012 [37] Fragile X syndrome FMR1 mutation linked phenotype andsignaling deficits Differentiated neurons
Risk
variant
carrier
Y
Madison et al., 2015
[38] BPD
Phenotypic alterations in BPD
progenitors rescued by WNT
inhibition
NPCs
Y (2)
(pedigree-
study)
N
Maekawa et al., 2015
[39] SCZ, ASD
Hair follicle is a potential biomarker
source
iPSC-derived
neurospheres Y Y
Marchetto et al., 2010
[40] Rett syndrome
Morphological and
electrophysiological anomalies
Panneuronal
differentiation protocol Y Y
Maschietto et al., 2015
[41] SCZ
Altered gene expression profile during
neurodevelopment NPCs Y (1) Y
Niedringhaus et al.,
2015 [42] Fragile X syndrome
Mobile raft minicultures developed for
high-throughput assays on neurons
Differentiated neurons
in microraft cultures Y (1) Y
Pas¸ca et al., 2011 [43] Timothy syndrome Disease-specific cellular phenotypeand differentiation
Cortical glutamatergic
neurons Y (2) Y
Paulsen et al., 2014 [44] SCZ Zinc and potassium imbalancereverted by valproate NPCs Y (2) N
Pedrosa et al., 2011 [45] SCZ 22q11.2 deletion delays differentiation Glutamatergic neurons Y (3) N
Robicsek et al., 2013
[46] SCZ
Impaired differentiation, maturation,
and mitochondrial dysfunction Dopaminergic neurons Y (3) N
Roussos et al., 2014 [47] SCZ CACNA1C variation disrupts generegulation through chromosome loops
Differentiated
glutamatergic neurons N Y
Shcheglovitov et al.,
2013 [48]
22q13.3 deletion
syndrome
SHANK3 and IGF1 correct excitatory
synaptic transmission deficit
Differentiated
glutamatergic neurons Y (2) N
Sheridan et al., 2011
[49] Fragile X syndrome Diminished neural differentiation
Differentiated neurons
and glia Y (3) Y
Shi et al., 2014 [50] Psychopharmacology Dopamine 2 receptor is mediated bymicroRNA-9 and microRNA-326 Dopaminergic neurons N Y
Tian et al., 2014 [51] Timothy syndrome Altered Ca
2+ signaling leads to
transcriptional dysregulation
Differentiated
glutamatergic neurons Y (3) Y
Topol et al., 2015 [52] SCZ Altered WNT signaling Forebrain patternedNPCs Y (4) N
Wang et al., 2014 [53] BPD Cell adhesiveness is associated withlithium response
Immature iNs,
lentiviral-based
transdifferentiation
Y (12) Y
Wen et al., 2014 [54] SCZ, MDD
DISC1 mutation causes synaptic
deficits and transcription
dysregulation
Glutamatergic
forebrain neurons Y (2) N
Williams et al., 2014
[55] Rett syndrome
MECP2 mutant astrocyte influences
negatively the morphology and
function of cocultured neurons
Astrocytes Y Y
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Author, publication
date Modeled disease(s) Main findings
Cell line,
differentiation protocol
Patient
derived
cell lines
Free
full text
Yoon et al., 2014 [56] SCZ 15q11.2 CNV results in neural stem celldeficit Neural rosettes, NPCs Y Y
Yu et al., 2014 [57] SCZ Deficit in hippocampal granule neurongeneration
Hippocampus dentate
gyrus granule cells Y (4) Y
Zeng et al., 2013 [58] Neurodevelopment
NRXN1 silencing impacts adhesion
and differentiation related
transcription
NPCs and
differentiated neurons N Y
∗ indicates data were not available.
ASD: autism spectrum disorders; BPD: bipolar disorder; iPSC: induced pluripotent stem cell; MDD: major depressive disorder; SCZ: schizophrenia; NPC:
neural progenitor cell.
(b)
Author(s) (31) Year of publication Disease(s)
Acab and Muotri 2015 [59] ASD
Aigner et al. 2014 [60] ASD
Ardhanareeswaran et al. 2015 [61] ASD
Brennand and Gage 2012 [62] Psychiatric disorders
Brennand et al. 2014 [63] SCZ
Buxbaum and Sklar 2011 [64] SCZ
Chailangkarn et al. 2012 [65] Neurodevelopmental disorders
Cheung et al. 2012 [66] Rett syndrome
Cundiff and Anderson 2011 [67] Neuropsychiatric disorders
Duan 2015 [68] SCZ
Freitas et al. 2014 [69] ASD
Ho et al. 2015 [70] Neuropsychiatric disorders
Cocks et al. 2014 [71] ASD
Kim 2010 [72] Psychiatric disorders
Kim et al. 2012 [73] ASD
Kim et al. 2014 [74] ASD
Ladran et al. 2013 [75] Neuropsychiatric disorders
Liu and Scott 2014 [76] ASD
Mackay-Sim et al. 2011 [77] Neuropsychiatric disorders
Muotri 2015 [78] ASD
O’Shea and McInnis 2015 [79] BPD
Pas¸ca et al. 2014 [80] Neuropsychiatric disorders
Paulsen et al. 2012 [81] SCZ
Paulsen et al. 2013 [82] Neurodevelopmental disorders
Prilutsky et al. 2014 [83] ASD
Qiang et al. 2014 [84] Neuropsychiatric disorders
Schadt et al. 2014 [85] Neuropsychiatric disorders
Tobe et al. 2013 [86] Psychopharmacology
Tran et al. 2013 [87] SCZ
Vaccarino et al. 2011 [88] Neuropsychiatric disorders
Viswanath et al. 2015 [89] BPD
Walsh and Hochedlinger 2010 [90] Rett syndrome
Wright et al. 2014 [91] SCZ
ASD: autism spectrum disorders; BPD: bipolar disorder; SCZ: schizophrenia.
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Key questions are as follows: What are we modeling?
(Which developmental and functional state of the in vivo
neurons?) What kind of indicators and assays should be used
for quality control? iPSCs are considered almost undistin-
guishable compared to human embryonic stem cells; and
iPSC derived NPCs form rosettes, analog to the neural tube,
the embryonic primordium of the central nervous system
[119]. Thus, it is reasonable to assume that we are modeling
fetal neurogenesis and neurodevelopment in cell cultures
under differentiation. Accordingly, Brennand et al. found
that the gene expression profile of NPCs and even 6-week-
old differentiated neurons resembles the first-trimester fetal
brain at the most [16]. Moreover, the electrophysiological
properties of stem cell derived neurons share common
temporal pattern with pyramidal neurons of the postnatal
animal neocortex [120].
However, we have to declare that our knowledge on pre-
and postnatal brain development is restricted and mainly
relies on animal and human fetal brain studies. This limited
insight and the in vitro observations underpin that iPSC
differentiation and iNC maturing follow the in vivo timeline
and stages and react to the same exogenous effects [93].
For instance, Boissart et al. demonstrated that the dif-
ferentiational potential of iNPCs follows a temporal manner
similar to what has been previously described in animal
models [14]. The group delayed cellular commitment with
high-mitogenic medium and sustained NPC proliferation for
passages 8–20. The prolonged proliferation period resulted
in a homogeneous late cortical progenitor population that
spontaneously differentiated into superficial cortical neurons.
Three weeks after withdrawal of mitogenic factors, more than
80% of the cells were glutamatergic. Importantly, the short,
synchronous, and highly productive differentiation period
makes this method amenable to high-throughput assays.
6.2. Doing Well in the Wells. Neurons, specified from pro-
genitor cells, are immature and require 4–12 weeks to reach
their definitive phenotype in vitro, which [119, 121, 122] is a
notable hampering factor of iNC studies. Literature proves
that detailed investigation of this period is crucial for the
following technical and validation reasons.
(1) First, transition from pluripotency to differentiated
neuronal state is attended by complex, pervasive gene expres-
sion changes. Fathi et al. analyzed the differentiation-related
transcriptome dynamics and revealed that 5955 transcripts
were modified during the 4-week-long protocol [123]. Of
note, 2589 transcripts were upregulated in the differentiated
neurons compared to pluripotent cells. On one hand, this
intensive, early period can be used to unveil and under-
stand neurodevelopmental disturbances and bridge between
disease-associated genotypes and endophenotypes. On the
other hand, experimental design, timing, and theories must
be set up circumspectly.
(2) Differentiation and maturation can be influenced
by the culturing conditions; therefore, several researches
proposed protocol modifications to shorten the “before-the-
experiment” period and improve synchronicity. For instance,
Tang et al. compared the neural maturation on two different
surfaces: the most frequently used artificial coating, laminin,
versus astrocyte layer [124]. Astrocytes promoted the differ-
entiation, soma and neurite growth, and dendrite arboriza-
tion. They supported functional maturation with regard to
ion channel and receptor expression and synaptic transmis-
sion. Still, even if cultured on astrocytes, neurons did not
exhibit matured synaptic activity before the third week, and
cells on laminin were further delayed. Astrocyte-conditioned
[125], ascorbic acid [126] and cAMP supplemented [123]
culturing medium or the application of graphene oxide
nanomaterial [127] also accelerates differentiation.
(3) We also cannot pass by the fact that the extended,
responsive maturation may lead to phenotypic heterogeneity
within the dish and result in a mix of progenitors and
immature, partially or fully matured neurons in different
ratios [13]. Additionally, NPCs and neurons display similar
appearance and NPCs express glutamate [128], GABA [129],
and dopamine [130] receptors.
6.3. Casting Neurons. Given the above-mentioned issues, we
suggest that every iPSC/iNC experiment should include the
developmental and functional characterization of the subject
cells. The main approaches for describing a neuron are as
follows: neural marker detection, receptor and ion channel
profiling, electrophysiological analysis, and the evaluation
of synaptic functions via enzyme activity, neurotransmitter
release, metabolism, and reuptake [131].
The methodology of neural marker detection developed
concomitantly with the differentiation protocols. Today, we
are able to generate and identify cortical excitatory gluta-
matergic pyramidal cells [102]; GABAergic inhibitory inter-
neurons [105]; cerebellar Purkinje cells [122]; or dopamin-
ergic neurons of the substantia nigra [131]. However, the
presence of the differentiationmarkers is not indicative of the
neuron’s maturation state.
The work of Dage et al. revealed that detailed pharmaco-
logical characterization of the differentiated neurons would
be much desired since the receptor and ion channel signature
of differentiated neurons may change almost day by day [24].
Furthermore, maturing iPSC-derived neurons do not display
NMDA receptor subunit switch, peculiar to the neonatal
brain [24], which might be a relevant difference between in
vitro and in vivo fashions.
Data suggest that electrophysiological assessment of
the cells might be the most potent approach for defining
maturation states. The electrophysiological development in
vitro resembles postnatal neocortical changes observed in
animal models. Namely, the resting membrane potential
becomes more negative, the duration of action potential
decreases, and the Na+, K+, and Ca2+ currents show time-
dependent changes [120]. The milestones are thought to
be the appearance of spontaneous excitatory postsynaptic
currents (sEPSC) and action potentials in fresh neurons [122]
and capability for repetitive action potentials in matured
neurons [13, 120, 131].
Belinsky et al. went further.They carried out patch clamp,
Ca2+ imaging, and PCR on single-cell level to correlate
the electrophysiological properties and the gene expression
pattern of differentiating and maturing neurons [13]. The
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cells demonstrated action potential already from day 15,
but expression of several neuronal physiology and disease-
associated genes were delayed until day 29 (COMT, DISC1,
DTNBP1,GAD1, andPAX6).These thought-provoking results
press for multimethod validation. Recently, Chatzidaki et al.
[132] demonstrated the detailed pharmacological character-
ization of nicotinic acetylcholine receptors on iPSC-derived
human neurons. The exact time points of the functional and
developmental stages highly depend on the cell type and the
culturing protocol; therefore, an orientating timeline with the
defined, critical landmarks and minimally required valida-
tion assays could assist the interpretation and reproducibility
of in vitro findings. Furtherly, high-throughput assays offer
the possibility to monitor the cell cultures around the clock,
analyze structural and functional alterations (e.g., synaptic
activity), and capture the right time to run hundreds of tests.
6.4. Neurons, into Single File! Weare only beginning to realize
the magnitude of heterogeneity in neuronal cultures derived
from iPSCs. Earlier lines of evidence already highlighted the
fact that, despite the utilization of targeted differentiation
protocols, neuronal cultures remain heterogeneous and give
rise to mixed populations of glutamatergic, GABAergic, and
dopaminergic neurons, as well as astrocytes and undifferenti-
ated cells. Recently, the development of single-cell approaches
makes it possible to determine the ratio of neurons versus
astroglia, neuronal subpopulations, or neurons reaching a
specific stage of maturation, within a population of differ-
entiating neurons. Neuron-to-neuron variation seems to be
a general feature of in vitro as well as in vivo neuronal
populations. Moreover the degree of variation also casts
light on faulty neurodevelopment associated with neuropsy-
chiatric disorders. Shcheglovitov et al. [48] used single-
cell methodology to analyze neuronal cultures derived from
patients suffering from Phelan-McDermid syndrome, a rare
condition caused by 22q13.3 deletion. Besides other major
findings, this outstanding paper also points out that only
a small proportion of neurons express postsynaptic density
proteins SHANK1–SHANK3, indicating small fraction of
synaptically mature neurons. 20–60% of neurons expressed
TBR1, CTIP2, and SATB2 upper layer cortical markers, while
less than 10% of neurons expressed GABAergic markers. In
their methodological summary, Citri et al. [133] provide a
protocol for single-iN qPCR and present data indicating the
low proportion of VGLUT1 and VGLUT2 expressing iNs,
suggesting delayed synaptic maturation in this system [134].
The described single-cell methodology has been successfully
incorporated in several other studies. While neuronal differ-
entiation protocols are much better characterized in recent
years, the above findings illustrate that single-cell approaches
are on the rise and will be important and necessary tools in
the armamentarium of in vitro neuronal disease modeling
efforts.
6.5. Thinking Big. Theoretical concepts of psychiatric dis-
orders changed radically in the recent decades: the immune-
neurodevelopmental model of SCZ and ASD [135], neuro-
inflammation-degeneration theory of MDD [136], and the
need for G×E and network-based diagnostic and therapeutic
approaches became widely accepted. But the revolution is
still delayed in psychopharmacology. One detrimental factor
can be the lengthy, expensive, and animal model based
testing of potential new targets and compounds. Therefore,
robotic high-throughput assays on human cell lines could
be milestones in the paradigm shift towards human biology
based, in vitro drug development [137]. iPSC/iNCs can be
optimal subjects for these studies.
Fragile X syndrome is neurodevelopmental disorder
caused by a silencing mutation of the FMR1 gene. Recently,
two independent research groups developed and published
high-throughput screening methods for FMR protein detec-
tion and novel drug identification using patient-derived
iNPCs [33, 138]. Kumari et al. designed a time-resolved flu-
orescence energy transfer (TR-FRET) based assay to measure
FMRP levels in 1 536wells and screen 1 280 pharmacologically
active compounds parallel to identify those which increase
the expression of the silenced gene [33]. The most effective
molecules were retested in a secondary assay using qRT-
PCR and further confirmed by dose-response experiment.
Kaufmann et al. used high-content screening to observe cell
morphology and FMRP expression alterations and tested the
efficacy and toxicity of 50 000 compounds [138]. Importantly,
automated high resolutionmicroscopy andmachine learning
algorithms allow single-cell-based follow-up and data analy-
sis in living cultures; therefore the group was able to detect
that a remarkable subpopulation of the cells (40%) responds
to certain drugs, although the averaged measures did not
reach significance.
Both works demonstrated a sensitive, cost-effective
approach for drug development. However, we have to add
that the utility of progenitor cells is frequently subopti-
mal or invalid in psychopharmacology; and current high-
throughput methods are optimized for proliferating, easily
transferable cell lines and not for postmitotic neurons [42,
139]. To reduce the technical difficulties, Niedringhaus et al.
worked out a transferable raftminiculturing practice for neu-
ron cultures which provide sufficient experimental material
for microvolume reactions and appropriate sample sizes [42].
Notably, the cell viability, sample-to-sample reproducibility,
and screening potential proved to be higher than those on
conventional well-plates.
An additional hampering factor might be the time-
consuming derivation and characterization of neurons from
somatic cells accompanied by several technical pitfalls.
Research industry offers several genetically modified iPSC-
derived neurons which can be a faster model for drug
development after thorough validation [125].
6.6. Double Standard: Stable and Flexible. The iPSC/iNC line
generation requires stem cell-like, incompact chromatin and
multiple epigenetic rearrangements. Controversially, scien-
tists agree that a high-quality iPSC/iNC assay conserves the
donor’s genetic information (including parental imprinting).
The NIMH meeting participants, and many since then,
conceived a reasonable concern on the genetic (un)stability
of induced cell lines [10].
Previously, chromosome aberrations, gene deletions/
duplications, and point mutations were thought to be the
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main mechanisms responsible for de novo mutations during
the pluripotent state. However, multiple studies demon-
strated that iPSCs and iNPCs exhibit chromosomal stability
(one examined 1700 stem cell cultures [140]). Per contra,
copy number variations (CNVs) show significant incidence
[23, 112]. All of the investigated cell lines gained CNVs and
the CNV signature of the iPSCs differed from both somatic
parent cells and iNCs. This indicates that de novo mutations
may appear through the somatic cell-iPSC-NPC-neuron
transitions. On the other hand, mosaicism for CNVs is also
common in vivo: it represents 0.12–7.3% of intraindividual
genomic variability [141].
Keeping in mind that CNVs are known to influence
clonal selection in cell cultures [142] and participate in the
etiology of several human diseases, including neurodevelop-
mental disorders (SCZ [143], ASD [31], and ADHD [144]),
the iPSC/iNC quality control calls for reconsideration. It
was always supposed but, recently, Kang et al. proved that
genetic integrity is highly influenced by the reprogramming
technique, and DNA nonintegrating protocols are safer [145].
Thepreviously recommended karyotyping is not sufficient for
ensuring validity; instead, DNA sequencing of the source and
generated cells is desirable.
6.7. The Neuronal Genome: Imperfectly Imitable? Somatic
mosaicism affects the brain also: brain-only or brain region-
only somaticmutations, chromosome aneuploidy,microdele-
tions, or retrotransposon dynamics have been detected in
post mortem brain tissue. Presumably, these neural genomic
variations contribute to the functional heterogeneity of
brain cells and also to the development of neuropsychiatric
disorders [146]. For instance, L1 retroelements (the only
human retrotransposon with autonomous activity) exhibit
increased copy number in adult NPCs compared to non-
brain cells and are known to be associated with Rett syn-
drome [147]. Bundo et al. examined the L1 signature in
SCZ using multiple model systems [18]. First, they showed
that L1 copy number is increased in the prefrontal cor-
tical neurons of SCZ patients compared to controls and
autologous nonbrain cells. To answer the question whether
this ensues from hereditary or environmental factors, the
group assessed the L1 profile in an environment-induced
SCZ animal model and in iNCs derived from SCZ patients
with rare mutation of large effect (22q11 deletion). The
genomicDNAof themouse brain exhibited the consequences
of high L1 activity and they also detected increased L1
insertion rate during in vitro neurogenesis. Moreover, brain-
specific L1 insertion sites were near or in genes involved
in synaptic functions and neuropsychiatric disorders sup-
porting the possible pathognomic role of retrotransposition
events. For conclusion, we can speculate that increased
L1 dynamics by environmental and/or genetic factors may
increase the susceptibility to neurodevelopmental disorders
by disrupting synaptic and schizophrenia related genes in
neurons.
This outstanding experimental design reassures the valid-
ity of iPSCs/iNCs in modeling neurodevelopment and calls
for further studies on the neuronal genome.
6.8. Designation of Origin. Besides the above-mentioned
somatic mosaicism, cellular commitment and in vivo cell-
aging raise the following question: Does the source cell type
matter? Neuropsychiatric studies apply the most frequently
easy-to-obtain lymphocytes, fibroblasts, and keratinocytes;
but, theoretically, all somatic cells can be reprogrammed or
transdifferentiated into iPSCs and iNCs.
These somatic cells widely vary in their epigenetics,
proliferative potential, and the rate of cellular aging. Previous
studies found that the intrinsic properties of the source
cells, that is, stage of differentiation [148], senescence [149],
tissue type [150], and number of passages [151], influence the
efficacy of reprogramming. Furthermore, the generated cells
display a residual gene expression pattern of the source cell
type referring to “incomplete reprogramming” and result in
variability among iPSCs from different tissue samples [152].
Chen et al. speculated that induced cell lines may
retain and transmit transcriptional/epigenetic marks from
the source tissue to the differentiated cells; therefore, they
carried out whole transcriptome analysis in neurons gained
from fibroblasts or dental pulp [20]. Notably, they found
63 differentially expressed genes, including a glutamate
receptor, choline, GABA, and glycine transporter. Striking
differences were found in the expression of the SLITRK2
gene (associated with BPD and ASD), multiple HOX genes,
and a set of transcription factors. Pathway analysis revealed
that neurological disease/schizophrenia related gene sets are
the most affected [20]. Unfortunately, the interpretation of
the results might be problematic since the dental pulp was
obtained from a 12-year-old male subject, while fibroblasts
originated from a 30-year-old female and a 58-year-old male.
However, the experiment is highly noteworthy: even if we
conclude that the source cell type or the donor’s age passed
down through generations and affected the gene expression
of the iNCs, it urges for further research.
6.9. Patients Ill Sorted? One of the main research principles
is representativeness: the sample has to be an unbiased illus-
tration of the studied population. Psychiatric diagnostic cate-
gories cover a wide range of patients with great heterogeneity
in etiological factors, symptomatology, disease progression,
and therapy response. This diversity issued several difficul-
ties in experimental and clinical settings during the past
decades.
Now, the overlook is changing: DSM-5 omitted the pre-
vious SCZ subtypes defined by clinical symptoms [153]. Two
years later, the Consortium on the Genetics of Schizophrenia
(COGS) postulated that endophenotypes could provide a
more negotiable approach of patient categorization for clini-
cal and research purposes [154]. Endophenotypes, for exam-
ple, cognitive dysfunction, EEG-markers, or brain imaging
phenotypes, are quantitative laboratory based measures with
a same level of heritability as SCZ itself [155]. They can
be linked to certain genotypes, cellular phenotypes, psy-
chopathologies, and functional impairments and fill the gene
to phene gap. The NIMH workshop in 2012 also addressed
the critical step of patient selection and recommended subject
recruitment based on comprehensive clinical, genetic, and
cellular characterization.
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6.10.The Art of Design. Disrupted in schizophrenia 1 (DISC1)
gene is known to be involved in fetal and adult neurode-
velopment and neuroplasticity, and its variations are highly
associated with a wide range of mental disorders: SCZ, BPD,
MDD, and ASD as well [156]. Presumably, it predisposes to
endophenotypes which can manifest themselves in different
clinical syndromes depending on the genetic and environ-
mental cofactors [157].
Wen et al. aimed to study cellular consequences of
the DISC1 mutation [54]. They derived iPSC lines from a
carrier pedigree: one SCZ and one MDD patient with a
DISC1 frameshift mutation, two unaffected family members
without the mutation, and one additional control: an unre-
lated healthy subject. The DISC1 mutation caused functional
synaptic transmission deficits in the glutamatergic neurons
via pervading transcriptome alterations. To challenge their
hypothesis on the primary pathognomic effect of the DISC1
mutation, the research group repeated the measures with
the isogenic pairs of the cell lines, generated by DNA
editing. Over and above the obvious values of their results
in understanding DISC1 related pathophysiology and filling
the gap between the genotype and the clinical picture with a
cellular endophenotype, this work provides a great example
for careful, overthought study design.
Considering that patient iPSC/iNC studies are usually
conducted on small sample sizes (1–5 persons/group) and
advancements are trending towards personalized medicine,
careful case-control matching in iPSC/iNC research is crucial
tomaintain validity and reliability.Whenmonogenic diseases
(e.g., Rett and Fragile X syndrome) are investigated, the
gender, age, and/or genotype based selection of healthy
individuals is sufficient. Per contra, in case of polygenic neu-
ropsychiatric disorders with intermediate heritability (30–
70%) other designs are noteworthy since the combined effect
of all disease-related and irrelevant alleles manifests itself in
the dish [158].
For instance, pedigree-studies allow identifying heri-
tability factors. Inclusion of affected and unaffected family
members reduces the genetic noise (heterogeneity) and thus
the risk of type I error. While a second, independent control
group from out-of-pedigree healthy subjects helps to oversee
the potential effects from family genetic background. Iso-
genic pairs produced by genetic correcting technologies (e.g.,
TALE nuclease [159], zinc finger nuclease [160], homologous
recombination [161], or CRISPR [162]) allow a cell line to be
its own control and enables the targeted testing of single gene
effects via excluding (epi)genetic diversity. In some cases (e.g.,
CNVs, trinucleotide repeats, and X-linked disorders), in vivo
or in vitromosaicism provides isogenic controls [26].
6.11. Psyche in the Dish? The question is not sceptic by all
means. How can we validate a specific iPSC/iNC line for
modeling a psychiatric disorder? Chromosomal and cellular
marker characterization and evaluation of genetic stability
are only the base of quality control. Having differentiated
neurons does not evidence a model for neurophysiology or
disease neuropathology.
Two research groups aimed the validation of a commer-
cially available neural cell line for further studies on ASD and
neurodegenerative diseases [1, 24, 125]. The corroboration
included whole transcriptome analysis, receptor and ion
channel profiling, and detailed electrophysiological charac-
terization. According to their results, the cells display early
developmental neural phenotype and express the majority of
ASD associated genes and thus this cell line might be utilized
as control in comparison to patient-derived cells or suitable
for isogenic mutant—wild type pair generation.
Interestingly, many of the ASD-related genes showed
changes along the culturing process [24], and Belinsky et
al. also detected specific temporal manner in the genes of
interest (DISC1, DTNBP1, GAD1, PAX6, FOXP1, FOXP2,
vGLUT1, and COMT) [13]. This sounds reasonable since the
mentioned genes are linked to neurodevelopment, synaptic
transmission, and intracellular signaling, functions highly
implicated during neural maturing. However, these obser-
vations are worthy of note, suggesting that timing can
easily enhance or undermine the validity of the experi-
ment, especially when the most frequently used early neural
and forebrain markers (PAX6 and vGLUT1 and GAD1) or
canonical disease genes (DISC1 and COMT) are the subjects.
Concordantly, Wen et al. found that DISC1 mutation caused
structural anomalies and synaptic dysfunction attenuate
around postdifferentiation weeks 4–6 [54].
Usually, experimental data can be embedded into pre-
vious results and legitimized by the cited literature. Con-
sidering the novelty of the field and the limited number of
research papers, iPSC/iNC researchers can rarely expect their
model’s validation from preceding experiments. Comparing
the results with animal model and human postmortem
findings can offer pivots; however, dissimilaritiesmight ensue
from differences between species and cell types since we are
matching pure neuron cultures with tissues [41].
6.12. Grafting Neurons for Psychiatric Treatment? Three
future applications of iPSCs and iNCs are most commonly
predicted [24]. As model systems, they can help us under-
stand the cellular pathophysiology of neuropsychiatric dis-
orders and reveal genotype-phenotype correlations. High-
throughput cellular screening assays may provide novel
targets in drug development; and, finally, iPSC-derived cells
may play a role in regenerative medicine.
Induced or embryonic PSC-based replacement therapy
research is one of the most expeditiously developing fields
of medicine. Currently, clinical trials are in progress in
macula degeneration, type I diabetes mellitus, ischemic
heart failure, and spinal cord injury [163]. Preclinical results
are also promising in Parkinson’s and Alzheimer’s disease,
neurodegenerative disorders with well-defined pathological
and functional alterations and cellular loss (recently reviewed
in [163, 164]). And what about other psychiatric disorders?
Animal models can provide us with hints about this appli-
cation.
For instance, SCZ has multifactorial origin which per-
vades the whole connectivity during neurodevelopment
and results in poorly understood brain pathology. Human
and animal research suggest that cortical and hippocampal
inhibitory interneuron deficit contributes to the dopamin-
ergic system dysfunction, thus the positive symptoms of
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SCZ [165]. In rodents, embryonic and induced human and
nonhuman NPC grafts survive, proliferate, migrate, and
differentiate spontaneously into pyramidal or GABAergic
neurons [166–168]. The integration of these inhibitory neu-
rons into the host neural circuits successfully modulated
the hyperactive dopaminergic system and the behavior
analogous of positive symptoms in a mouse SCZ model.
While these engraftment experiments are perplexing and can
contribute substantially to our understanding of the neurobi-
ology of psychiatric disorders, they donot necessarily forecast
engraftment of in vitro differentiated neurons as a feasible
approach for the treatment of psychiatric disorders in the
near future. Disease pathology remains poorly understood
and the clinical hurdles are also numerous.
6.13. Open Access in Stem Cell Based Disease Modeling. The
NIMH workshop addressed one more intensively discussed,
still actual issue: information and resource sharing which
is especially meaningful in the rapidly developing scientific
fields such as iPSC/iNC research [10].The participants argued
that open sharing of data and standardization of iPSC/iNC
generation and validation protocols are essential for improv-
ing experimental reproducibility.
It is well known that open sharing and collaborative
environment empower knowledge circulation and thus fuels
innovation and discovery. Therefore, decision-makers took
significant steps to implement the open access policy: in
2015, both the European Commission and the US Congress
supported the proposal that articles on publicly funded
researches have to be freely available for anyone [169, 170].
We were curious if this open access movement is observable
in the iPSC/iNC literature.We found that 73%of the reviewed
research papers are freely accessible (35 from48 articles, listed
in Table 2(a)).
The other basis of open science is resource sharing.
Growing number of cell banks collect somatic cells and/or
iPSCs from patients with neuropsychiatric disorders and
assure accessibility for the scientific community on request
[17, 171]. Such (inter)national consortiums and collaborations
provide standardized databases and methodology, increased,
homogenous sample quality, and possibility to study rare
genetic or phenotypic variations, affected families, or—as
seen in Sweden—isogenic cell line pairs from monozygotic
twins [172].
7. Tools in Our Hands:
We Have Nothing to Fear
The ideal cell culturemodel for in vitro experimentsmeets the
following requirements: (1) it is easily obtainable via minimal
invasive intervention; (2) the initiation and maintenance of
the cell culture are not extremely labor intensive or time-
consuming; (3) the fact that differentiation, if necessary,
can be directed and monitored; (4) the cell line reserves
proliferative, self-sustaining capacity over passages; (5) and
this is done with genetic stability; (6) it exhibits similar (or
identical) pathophysiological features to the diseased tissue in
vivo; and (7), last but not least, the method provides enough
experimental material at reasonable expenses.
Revising the currently available in vitro systems, the
words of Salvador Dali flash on: “Have no fear of perfection
– you’ll never reach it.” Ideal in vitro model cannot exist,
but depending on the concept of the research and the
accessible resources one can choose the most optimal from
the following.
Extended literature discusses peripheral cells, such as
blood leukocytes and dermal fibroblasts, as potential in
vitro models and biomarker sources of mental disorders.
They are relatively easy-to-obtain, robust cell lines and
share receptor and signaling pathway similarities with CNS
cells [173–175]. Fibroblasts have self-maintaining capacity
ab ovo and maintain homogeneity between passages 5 and
20 [176]. Freshly isolated leukocytes are appropriate even
for bedside functional assays or can be immortalized for
culturing but represent poor genetic stability [177]. Finally,
we cannot disregard that peripheral cells do not permit the
examination of specific neural phenomena (e.g., electrophys-
iology, microarchitecture, and neurodevelopment).
Human primary neural cultures, initiated from brain
biopsies, are barely applied to neuroscience.They require spe-
cial conditions and lack self-maintaining capacity; therefore,
the amount of experimental material is restricted. Furtherly,
the cells are already tainted with life-long in vivo effects,
which balks the expression of the na¨ıve endophenotype.
Since 2006, when Takahashi and Yamanaka showed that
the expression of four transcription factors can reprogram
adult somatic cells into an earlier ontogenic state [98],
induced pluripotent stem cells (iPSCs) and iPSC-derived cell
lines became one of the most studied and advancing fields of
medicine; but, as seen above, we still face numerous technical
or theoretical issues.
8. Can We Make a Long Story Short?
The main concerns about iPSC-research, that is, time and
resource demands, genetic instability, epigenetic changes, and
populational heterogeneity, might be partially overcome by
omission of the pluripotent state and direct transdifferen-
tiation of somatic cells into completely different cell types.
After Takahashi and Yamanaka introduced the method of
cellular reprogramming, researchers started to work on new
protocols to establish neural cultures from somatic cells by
direct cell lineage conversion. Vierbuchen et al. were the
first who successfully transdifferentiated mouse fibroblasts
into functional neurons [95]. Since then, they and others
showed that human somatic cells (e.g., fibroblasts [134], blood
cells [178], and hepatocytes [179]) can be transdifferentiated
into neural progenitor cells [180] or postmitotic neurons
via forced expression or exogenous addition of transcription
factors,microRNAs, or smallmolecules.Moreover, one single
factor is enough to induce neural cell fate [181] and cell
type-specific factors allow the generation of dopaminergic
[182], motor neurons [183] or oligodendrocytes [184]. The
induced neural cells resemble in vivo neurons in their
functional, electrophysiological, translational characteristics
and form functional synapses; thus, they can be valuable
in vitro models of neuropsychiatric disorders. However, as
of yet only one experiment has been published on direct
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reprogramming in the context of psychiatric disorders.Wang
et al. [53] used lentiviral transduction with a construct
expressing miR-9/9∗-124, NEUROD2, ASCL1, andMYT1L to
transdifferentiate fibroblasts from bipolar patients responsive
or unresponsive to lithium medication, the gold standard
of mood-stabilizing treatments. iNCs derived from lithium-
responders and lithium-nonresponders demonstrated differ-
ent cell adhesion characteristics. This innovative approach
demonstrates the translation potential and “nearly bedside”
application of transdifferentiation-based assays.
The greatest advantage of direct lineage conversion is
bypassing pluripotent states and avoiding potential onco-
genicity as a consequence. On the other hand, this stability,
that is, lack of self-renewal and potential amplification,
might be a drawback in laboratory research and regenerative
medicine. Besides, the possibility of residuals from in vivo
cellular senescence and epigenetic memories inherited from
the parental tissue deserves further considerations [185].
9. The Undeservedly Neglected:
Glia-Associated Pathologies
Vast majority of psychiatric research deals with neurons but
they account for only about one-third of human brain cells.
Glial cells are responsible for maintaining brain homeostasis
and neural well-being. They provide lactate as source of
energy, regulate the redox balance, metabolic clearance, and
CNS immunology [186, 187], and play crucial role in directing
neuronalmigration, neurite outgrowth, and synaptic pruning
[188]. Additionally, astrocytes are in bidirectional cross talk
with neurons, and glial neurotransmission has been proposed
to be involved in several mental functions (e.g., memory,
motor control, and decision making) and neuropsychiatric
disorders [189]. Postmortem human and animal studies
proved that glial cells contribute to the development and
progression of psychiatric disorders and can be potential
therapeutic targets [190, 191].
NPCs derived from iPSCs can be differentiated into glial
precursors and mature astrocytes and oligodendrocytes [192,
193]. Microglial-like cells are even more easily obtainable
due to their mesodermal origin, and circulating monocytes
can be transdifferentiated within 14 days [194]. These cell
lines are underrepresented in psychiatric research, only used
as a feeder/supporting layer for the neurons. Per contra,
they are intensively studied as potential disease models and
therapeutical targets in neurological disorders, for example,
Huntington disease [195], amyotrophic lateral sclerosis [196]
or congenital hypomyelination [197], and intellectual disabil-
ity [198].
Yet, we can find a great example: how neuron-glia cocul-
tures can help to answer whether certain glia-associated
pathologies are pathognomic factors, additive part of the
endophenotype, or reactive (beneficial) response to the neu-
ral dysfunction. Williams et al. differentiated astrocytes and
neurons from iPSCs of Rett syndrome patients and demon-
strated that mutant astrocytes have non-cell-autonomous
adverse effects both on cocultured mutant and on healthy
neurons [55]. The group also proved that this impact is
directed by the extracellular environment since the astroglia-
conditioned media took the same detrimental effect on the
morphology and function of wild type and mutant neuronal
cultures. The adverse effects could be rescued by IGF-1
supplementation which underpins the ongoing IGF-1-based
clinical trials in the treatment of Rett syndrome. Surprisingly,
the efficiency of IGF-1 supplementation depended on the
genotype of the astrocyte, which calls for further pharma-
cogenetic studies. According to these findings, the effects of
the mutations in the astrocytes and neurons appear to be
additive. Similar innovative studies will unravel the complex
association of human neurons and glial cells in healthy and
diseased brains.
10. Limitations
On the whole, results are reassuring.Those who reported dif-
ferentiation and maturation anomalies in iNCs from patients
with neurodevelopmental disorders [37, 41, 43, 45, 46, 49]
are more than those who could not detect alterations during
differentiation [14] or in electrophysiological properties [13,
54]. However, there are some noteworthy study design and
publication biases.
(1) Scalability represents a central issue for stem cell based
disease modeling. Ideally, the number of cell lines derived
from specific patients could be scaled up to numbers typical
for clinical studies, meaning tens or hundreds of patients.
Realistically seen, today this is not feasible. However wemust
keep in mind that this method is in its infancy and the task
remains the exploration of cell lines derived from genetically
and clinically well characterized individuals.
(2) A priori hypotheses influence the objectives and the
measured parameters. Differentiation is intensively moni-
tored in these diseases; therefore, such small-scale variations
like 12% nuclear size differences can be detected [11], but less
is known about the transcriptome or receptor profile alter-
ations. (3) Majority of the studies examined the iPSC/iNC
lines at rest in monotonous environments which might be
detrimental during neurodevelopment, that is, specialization
for signal detection and transmission.Therefore environmen-
tal challenges could enhance and reveal additional differences
as showed in [29, 36]. (4) Great proportion of these differ-
ences might affect synaptic transmission which is understud-
ied in iPSC/iNC models; however, novel visualization and
high-content screening technologies might bring advances to
this field. For instance, functional assays of DISC1 mutant
cells, namely, spontaneous synaptic current measurement
and synaptic vesicle staining in living cells, revealed synaptic
vesicle release defect which were also observable in the
transcriptome [54].
(5) Similarly, there is a rate shift towards pervasive,mono-
genic neurodevelopmental syndromes with early-childhood
presentation and well-defined clinical and genetical picture.
The nature of these syndromes differs substantially from
the most frequent adult psychiatric disorders which are
multifactorial with less robust pathology and might show
themselves in the connectome and not on the single-cell level.
(6) Additionally, in case of polygenic disorders, the discrete
phenotypic alterations might be very small, presented on a
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continuous spectrum. In contrast, iPSC/iNC studies usually
recruit psychiatric patients with rare mutations of large
effects. Selection of severe cases based on the polygenic
score method could be a possible approach to overcome this
limitation.
11. Take Home Messages
This review demonstrates the unprecedented possibilities
offered by iPSC based in vitro disease modeling in psychiatry,
a field ofmedicine awaitingmajor developments. It is striking
how fragmented our understanding is about molecular dis-
ease pathways underlying SCZ, BPD, and ASD and how high
the level of unmet needs is among patients suffering from
these disorders. Incomplete therapeutic response, therapy-
resistance, and cognitive deterioration are all major hurdles
in the treatment of psychiatric patients. In vitro disease
modeling will help us with diagnostics by demonstrating
the heterogeneity within clinical disease groups in terms
of molecular disease mechanisms. This question, whether
similar clinical phenotypes share molecular foundations or
are rather determined by a final common pathway, remains a
central idea in psychiatry. Stem cells could also contribute to
treatment by paving theway to personalized pharmacological
treatment and drug screening as detailed in the review.
The prospects of stem cell based disease modeling cannot
be exactly foreseen; however, based on the past few years’
developments we can envisage major breakthroughs in stem
cell based psychiatry for the benefit of our patients.
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